Literature DB >> 31534029

Economic burden of multimorbidity in patients with severe asthma: a 20-year population-based study.

Wenjia Chen1, Abdollah Safari2, J Mark FitzGerald3, Don D Sin4, Hamid Tavakoli5, Mohsen Sadatsafavi6.   

Abstract

BACKGROUND: The economic impact of multimorbidity in severe or difficult-to-treat asthma has not been comprehensively investigated. AIMS: To estimate the incremental healthcare costs of coexisting chronic conditions (comorbidities) in patients with severe asthma, compared with non-severe asthma and no asthma.
METHODS: Using health administrative data in British Columbia, Canada (1996-2016), we identified, based on the intensity of drug use and occurrence of exacerbations, individuals who experienced severe asthma in an incident year. We also constructed matched cohorts of individuals without an asthma diagnosis and those who had mild/dormant or moderate asthma (non-severe asthma) throughout their follow-up. Health service use records during follow-up were categorised into 16 major disease categories based on the International Classification of Diseases. Incremental costs (in 2016 Canadian Dollars, CAD$1=US$0.75=₤0.56=€0.68) were estimated as the adjusted difference in healthcare costs between individuals with severe asthma compared with those with non-severe asthma and non-asthma.
RESULTS: Relative to no asthma, incremental costs of severe asthma were $2779 per person-year (95% CI 2514 to 3045), with 54% ($1508) being attributed to comorbidities. Relative to non-severe asthma, severe asthma was associated with incremental costs of $1922 per person-year (95% CI 1670 to 2174), with 52% ($1003) being attributed to comorbidities. In both cases, the most costly comorbidity was respiratory conditions other than asthma ($468 (17%) and $451 (23%), respectively).
CONCLUSIONS: Comorbidities accounted for more than half of the incremental medical costs in patients with severe asthma. This highlights the importance of considering the burden of multimorbidity in evidence-informed decision making for patients with severe asthma. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Health Economist; asthma epidemiology; systemic disease and lungs

Mesh:

Year:  2019        PMID: 31534029     DOI: 10.1136/thoraxjnl-2019-213223

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  2 in total

1.  A territory-wide study on the factors associated with recurrent asthma exacerbations requiring hospitalization in Hong Kong.

Authors:  Ka Pang Chan; Fanny Wai San Ko; Kwun Cheung Ling; Pik Shan Cheung; Lee Veronica Chan; Yu Hong Chan; Yi Tat Lo; Chun Kong Ng; Macy Mei-Sze Lui; Kwok Sang Wilson Yee; Cee Zhung Steven Tseng; Pak Yiu Tse; Mo Lin Maureen Wong; Kah Lin Choo; Wai Kei Lam; Chun Man Wong; Sheng Sheng Ho; Chung Tat Lun; Christopher Kei Wai Lai
Journal:  Immun Inflamm Dis       Date:  2021-03-03

2.  Chronic oral corticosteroids use and persistent eosinophilia in severe asthmatics from the Belgian severe asthma registry.

Authors:  S Graff; S Vanwynsberghe; G Brusselle; S Hanon; C Sohy; L J Dupont; R Peche; A Michils; C Pilette; G Joos; R E Louis; F N Schleich
Journal:  Respir Res       Date:  2020-08-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.